KES CARDIAC DIAGNOSTICS LTD

Company Registration Number:
14021176 (England and Wales)

Unaudited statutory accounts for the year ended 30 April 2024

Period of accounts

Start date: 01 May 2023

End date: 30 April 2024

KES CARDIAC DIAGNOSTICS LTD

Contents of the Financial Statements

for the Period Ended 30 April 2024

Company Information - 3
Report of the Directors - 4
Profit and Loss Account - 5
Balance sheet - 6
Additional notes - 8

KES CARDIAC DIAGNOSTICS LTD

Company Information

for the Period Ended 30 April 2024




Director: Kate Spelman
Registered office: 26
Zig Zag Road
Liverpool
England
L12 9EQ
Company Registration Number: 14021176 (England and Wales)

KES CARDIAC DIAGNOSTICS LTD

Directors' Report Period Ended 30 April 2024

The directors present their report with the financial statements of the company for the period ended 30 April 2024

Principal Activities

Perform cardiac diagnostics.

Directors

The directors shown below have held office during the whole of the period from 01 May 2023 to 30 April 2024
Kate Spelman

This report was approved by the board of directors on 22 January 2025
And Signed On Behalf Of The Board By:

Name: Kate Spelman
Status: Director

KES CARDIAC DIAGNOSTICS LTD

Profit and Loss Account

for the Period Ended 30 April 2024


Notes

2024
£
13 months to
30 Apr 2023
£
Turnover 4,875 -
Cost of sales ( 0 ) -
Gross Profit or (Loss) 4,875 -
Income from coronavirus (COVID-19) business support grants 0 -
Distribution Costs ( 0 ) -
Administrative Expenses ( 1,248 ) -
Operating Profit or (Loss) 3,627 -
Profit or (Loss) Before Tax 3,627 -
Profit or (Loss) for Period 3,627 -

The notes form part of these financial statements

KES CARDIAC DIAGNOSTICS LTD

Balance sheet

As at 30 April 2024


Notes

2024
£
13 months to
30 Apr 2023
£
Fixed assets
Total fixed assets: - -
Current assets
Cash at bank and in hand: 3,627 4,718
Total current assets: 3,627 4,718
Net current assets (liabilities): 3,627 4,718
Total assets less current liabilities: 3,627 4,718
Provision for liabilities: ( 0 ) ( 0 )
Accruals and deferred income: ( 0 ) ( 0 )
Total net assets (liabilities): 3,627 4,718

The notes form part of these financial statements

KES CARDIAC DIAGNOSTICS LTD

Balance sheet continued

As at 30 April 2024


Notes

2024
£
13 months to
30 Apr 2023
£
Capital and reserves
Called up share capital: 3,627 4,718
Shareholders funds: 3,627 4,718

For the year ending 30 April 2024 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 22 January 2025
And Signed On Behalf Of The Board By:

Name: Kate Spelman
Status: Director

The notes form part of these financial statements

KES CARDIAC DIAGNOSTICS LTD

Notes to the Financial Statements

for the Period Ended 30 April 2024

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

KES CARDIAC DIAGNOSTICS LTD

Notes to the Financial Statements

for the Period Ended 30 April 2024

  • 2. Employees


    2024
    13 months to
    30 Apr 2023
    Average number of employees during the period 11 1

KES CARDIAC DIAGNOSTICS LTD

Notes to the Financial Statements

for the Period Ended 30 April 2024

  • 3. Off balance sheet disclosure

    No